Submitted Successfully!
To reward your contribution, here is a gift for you: A free trial for our video production service.
Thank you for your contribution! You can also upload a video entry or images related to this topic.
Version Summary Created by Modification Content Size Created at Operation
1 -- 930 2023-09-26 07:05:21 |
2 correct format Meta information modification 930 2023-09-28 08:02:49 |

Video Upload Options

Do you have a full video?

Confirm

Are you sure to Delete?
Cite
If you have any further questions, please contact Encyclopedia Editorial Office.
Greco, C.W.; Hall, J.M. Diabetic Kidney Disease: Goals for Management, Prevention, and Awareness. Encyclopedia. Available online: https://encyclopedia.pub/entry/49622 (accessed on 18 May 2024).
Greco CW, Hall JM. Diabetic Kidney Disease: Goals for Management, Prevention, and Awareness. Encyclopedia. Available at: https://encyclopedia.pub/entry/49622. Accessed May 18, 2024.
Greco, Callie W., Julianne M. Hall. "Diabetic Kidney Disease: Goals for Management, Prevention, and Awareness" Encyclopedia, https://encyclopedia.pub/entry/49622 (accessed May 18, 2024).
Greco, C.W., & Hall, J.M. (2023, September 26). Diabetic Kidney Disease: Goals for Management, Prevention, and Awareness. In Encyclopedia. https://encyclopedia.pub/entry/49622
Greco, Callie W. and Julianne M. Hall. "Diabetic Kidney Disease: Goals for Management, Prevention, and Awareness." Encyclopedia. Web. 26 September, 2023.
Peer Reviewed
Diabetic Kidney Disease: Goals for Management, Prevention, and Awareness

Diabetic kidney disease (DKD), which is diagnosed on the basis of reduced glomerular filtration rate (GFR), increased albuminuria, or both, is the leading cause of chronic kidney disease (CKD) and end-stage renal disease (ESRD) worldwide. Future projections anticipate a significant increase in diabetes cases, with close to 700 million diabetes patients internationally by the year 2045. Amidst ongoing research into novel biomarkers and therapeutic agents for DKD, the current clinical preventative strategy for DKD involves (1) intensive glycemic control, (2) treatment of associated co-morbidities (hypertension and hyperlipidemia), and (3) instruction on lifestyle modifications, including smoking cessation, exercise, and dietary habits. In addition to these three categories, patient education on renal injury, a fourth category, is equally important and necessary in the collaborative effort to reduce global rates of DKD. In this entry, authors highlight and discuss these four core categories for DKD prevention.

diabetes chronic kidney disease diabetic kidney disease prevention glycemic index patient education lifestyle modification
Chronic kidney disease (CKD) is defined as the long term, progressive decline in kidney function due to accumulated renal damage. As renal injury accrues, CKD can eventually transition to its final stage, a devastating and costly complication, referred to as end-stage renal disease (ESRD). At ESRD, one of two permanent measures must be implemented to replace the failing kidneys. Patients will either need a renal transplant or an initiation of life-long hemodialysis therapy.
Future projections anticipate a significant increase in diabetes cases, with close to 700 million diabetes patients internationally by the year 2045 [1]. According to the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), there are several risk factors which can contribute to CKD development. These include drug-induced or infection-induced kidney injury, systemic autoimmune diseases, such as lupus and Goodpasture’s syndrome, or genetic conditions, like polycystic kidney disease [2]. However, the two most common causes for renal injury leading to CKD are hypertension and diabetes, with the latter being the leading cause of CKD [2][3]. Globally, diabetic nephropathy (DN), commonly referred to as diabetic kidney disease (DKD), contributes to over two-thirds of all CKD cases [4].
Diabetic kidney disease (DKD) is defined by both physiological and structural pathologic alterations. Three classic maladaptive renal changes are seen on histologic examination: nodular glomerulosclerosis, mesangial cell expansion, and fibrosis of the glomerular and tubular basement membranes [5][6]. The progressive parenchymal injury interferes with the vital metabolic and homeostatic functions of the kidney. As a result, the objective evidence used for DKD diagnosis involves a gradual decrease in the estimated glomerular filtration rate (eGFR) and progressive micro- to macro-albuminuria [7]. GFR and urinary albumin levels are categorized and correlated with the sequential CKD stages (1 through 4) and ESRD (stage 5). Among those with type 1 diabetes, up to 40% of patients are diagnosed with DKD within 15–20 years of diabetes onset [8]. For type 2 diabetes patients, the UK Prospective Diabetes Study (UKPDS) reported that more than 50% of patients develop DKD after an average of 15 years post-diabetes diagnosis [9]. As many as 20% of newly diagnosed type 2 diabetes patients already have signs of renal disease at the time of their diabetes diagnosis [10]. There also exists a prolonged asymptomatic phase of DKD, where renal injury is occurring but at a level undetectable by serum and urinary screening tests [11].
DKD is unfortunately a very prevalent consequence of long-term inadequate disease control in both type 1 and type 2 diabetes populations. The 2017 National Diabetes Statistics Report released by the Center for Disease Control (CDC), estimated that in 2015 diabetes affected approximately 30.3 million people of all ages (9.4% of the U.S. population). Among all individuals with diabetes, type 2 diabetes accounted for about 95% of the cases [12]. There is a similar concerning upward trend in diabetes worldwide, especially with type 2 diabetes in low- and middle-income countries largely due to the ongoing obesity pandemic [12][13]. The International Diabetes Federation (IDF) recently published the 2019 results on current global diabetes rates, including future disease projections. The report identified that 436 million adults, ages 20–79, are currently living with diabetes. Furthermore, the IDF report estimated that by the year 2045, there will be near 700 million people worldwide with diabetes [13].
Even more troubling is the simultaneous rise in the diabetes-associated mortality rate, which in 2019, accounted for 4.2 million deaths globally [13]. Diabetes is known to significantly reduce total life expectancy compared to non-diabetic populations. In fact, current statistics suggests a 6-year decrease in total life expectancy in those with a diabetes diagnosis [14]. Within the diabetes population, cardiovascular (CV) disease (coronary heart disease, stroke, heart failure) remains a prevalent cause of death. Although the majority of diabetes deaths are the result of CVD, recent reports have highlighted the steady incline in DKD-attributed mortality. A risk analysis study published by the American Diabetes Association (ADA) found an increase in all-cause mortality rates in diabetes cohorts compared to non-diabetes cohorts, even after adjusting for age, BMI, systolic blood pressure, and total and HDL cholesterol [15]. Specifically, there was a strong positive correlation between chronic diabetes and death from associated complications, including renal nephropathy and fatty liver disease.
In an effort to reduce the global burden of DKD, as well as DKD-associated mortality, it is critically important to address the risk factors for DKD in diabetes populations. The primary modifiable risk factors for DKD include uncontrolled glycemic index, hypertension and hyperlipidemia co-morbidities, and lifestyle factors (smoking, poor nutrition, and minimal exercise) [5][16][17]. Since the incidence of diabetes is expected to significantly rise over the next couple of decades, it is equally necessary to inform and educate at-risk diabetes patients on the potential end-organ complications resulting from inadequate diabetes management. This entry will review the current preventative approach for DKD, including strict glycemic control, treatment of hypertension and hyperlipidemia, promotion of patient-driven lifestyle modifications, and incorporation of point-of care patient education.

References

  1. Saeedi, P.; Petersohn, I.; Salpea, P.; Malanda, B.; Karuranga, S.; Unwin, N.; Colagiuri, S.; Guariguata, L.; Motala, A.A.; Ogurtsova, K.; et al. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9(th) edition. Diabetes Res. Clin. Pract. 2019, 157, 107843.
  2. National Institute of Diabetes and Digestive and Kidney Diseases. Causes of Chronic Kidney Disease. Available online: https://www.niddk.nih.gov/health-information/kidney-disease/chronic-kidney-disease-ckd/causes (accessed on 2 May 2020).
  3. Alicic, R.Z.; Rooney, M.T.; Tuttle, K.R. Diabetic Kidney Disease: Challenges, Progress, and Possibilities. Clin. J. Am. Soc. Nephrol. 2017, 12, 2032–2045.
  4. Winocour, P.H. Diabetes and chronic kidney disease: An increasingly common multi-morbid disease in need of a paradigm shift in care. Diabet. Med. 2018, 35, 300–305.
  5. Lin, Y.C.; Chang, Y.H.; Yang, S.Y.; Wu, K.D.; Chu, T.S. Update of pathophysiology and management of diabetic kidney disease. J. Formos. Med. Assoc. 2018, 117, 662–675.
  6. Qi, C.; Mao, X.; Zhang, Z.; Wu, H. Classification and Differential Diagnosis of Diabetic Nephropathy. J. Diabetes Res. 2017, 2017, 8637138.
  7. Association, A.D. Microvascular Complications and Foot Care: Standards of Medical Care in Diabetes-2020. Diabetes Care 2020, 43, S135–S151.
  8. Bennett, K.; Aditya, B.S. An overview of diabetic nephropathy: Epidemiology, pathophysiology and treatment. J. Diabetes Nurs. 2015, 19, 61–67.
  9. King, P.; Peacock, I.; Donnelly, R. The UK prospective diabetes study (UKPDS): Clinical and therapeutic implications for type 2 diabetes. Br. J. Clin. Pharmacol. 1999, 48, 643–648.
  10. Papadopoulou-Marketou, N.; Chrousos, G.P.; Kanaka-Gantenbein, C. Diabetic nephropathy in type 1 diabetes: A review of early natural history, pathogenesis, and diagnosis. Diabetes Metab. Res. Rev. 2017, 33, e2841.
  11. Ioannou, K. Diabetic nephropathy: Is it always there? Assumptions, weaknesses and pitfalls in the diagnosis. Hormones 2017, 16, 351–361.
  12. Bluher, M. Obesity: Global epidemiology and pathogenesis. Nat. Rev. Endocrinol. 2019, 15, 288–298.
  13. Ali, M.K.; Siegel, K.R.; Chandrasekar, E.; Tandon, R.; Montoya, P.A.; Mbanya, J.C.; Chan, J.; Zhang, P.; Narayan, K.M. Diabetes: An Update on the Pandemic and Potential Solutions. In Cardiovascular, Respiratory, and Related Disorders; Prabhakaran, D., Anand, S., Gaziano, T.A., Mbanya, J.C., Wu, Y., Nugent, R., Eds.; The International Bank for Reconstruction and Development/The World Bank: Washington, DC, USA, 2017.
  14. Rao Kondapally Seshasai, S.; Kaptoge, S.; Thompson, A.; Di Angelantonio, E.; Gao, P.; Sarwar, N.; Whincup, P.H.; Mukamal, K.J.; Gillum, R.F.; Holme, I.; et al. Diabetes mellitus, fasting glucose, and risk of cause-specific death. N. Engl. J. Med. 2011, 364, 829–841.
  15. Baena-Díez, J.M.; Peñafiel, J.; Subirana, I.; Ramos, R.; Elosua, R.; Marín-Ibañez, A.; Guembe, M.J.; Rigo, F.; Tormo-Díaz, M.J.; Moreno-Iribas, C.; et al. Risk of Cause-Specific Death in Individuals with Diabetes: A Competing Risks Analysis. Diabetes Care 2016, 39, 1987–1995.
  16. MacIsaac, R.J.; Jerums, G.; Ekinci, E.I. Glycemic Control as Primary Prevention for Diabetic Kidney Disease. Adv. Chronic Kidney Dis. 2018, 25, 141–148.
  17. Umanath, K.; Lewis, J.B. Update on Diabetic Nephropathy: Core Curriculum 2018. Am. J. Kidney Dis. 2018, 71, 884–895.
More
Information
Contributors MDPI registered users' name will be linked to their SciProfiles pages. To register with us, please refer to https://encyclopedia.pub/register : ,
View Times: 422
Online Date: 26 Sep 2023
1000/1000